Northern Oil & Gas
Stifel analysts remain very positive on this small-cap energy play. Northern Oil & Gas Inc. (NYSE: NOG) is engaged in the acquisition, exploration, development and production of oil and natural gas properties, primarily in the Bakken and Three Forks formations within the Williston Basin in North Dakota and Montana. It is the largest non-operator in that basin.
With Bakken returns continuing to improve to well above 50%, and Northern’s operating partners representing what may be as the best operators in the basin, there is upside potential.
The company pre-announced solid third-quarter production activity, and while the weather curtailed some results, the company kept 2019 final estimates intact. It was noted this week the company is expected to have free cash flow equal to almost three-quarters of the stock market capitalization over the next year.
The monster $5.70 Stifel price target compares the posted consensus target of $3.42 and the closing share price of $2.06 seen on Friday.
This small-cap biotech stock has serious upside possibilities. Syros Pharmaceuticals Inc. (NASDAQ: SYRS) engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited regions of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.
The firm focuses on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines and recently presented new preclinical data for SY-5609, its highly selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7). The data demonstrate that SY-5609 induces deep and sustained anti-tumor activity, including complete regressions, in multiple preclinical models of solid tumors at doses below the maximum tolerated dose. These data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Oppenheimer has set its price objective at $11. The consensus target is higher at $13.50, but the stock ended the week at $5.34.
This very aggressive tech play could have upside above the Jefferies target. Zynga Inc. (NASDAQ: ZNGA) is a leading developer of mobile and social games. In the company’s relatively short history, it has developed a broad portfolio of games that includes several on Facebook and several top-grossing mobile apps. Key franchises include FarmVille, Zynga Poker, Hit It Rich Slots and Words With Friends.
With live events growing the company’s revenues, cost-cutting should drive margin expansion, which is very positive. The company also pops up in takeover chatter, and the low price makes it even more attractive.
Zynga posted a healthy top and bottom line third-quarter beats, coupled with an above consensus fourth-quarter guide. The Jefferies analysts continue to believe investors are too focused on potential near-term M&A and are overlooking the fundamental strength in the core business. They view Zynga as the best way to play the industry tailwinds within mobile gaming.
The Jefferies price target is $7.50. The consensus target price is $7.41, and the shares were changing hands on Friday’s close at $6.35 apiece.
These five stocks for aggressive accounts looking to get share count leverage on stocks have sizable upside potential. While not suited for all investors, these are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.